National Pension Service Has $21.65 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

National Pension Service lessened its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 36.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 520,738 shares of the company’s stock after selling 293,155 shares during the period. National Pension Service owned approximately 0.14% of Moderna worth $21,652,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in MRNA. State Street Corp lifted its position in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares during the last quarter. Two Sigma Advisers LP acquired a new position in shares of Moderna during the 3rd quarter worth about $23,825,000. Douglas Lane & Associates LLC lifted its position in shares of Moderna by 62.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock worth $32,175,000 after purchasing an additional 298,715 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Moderna by 6.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock worth $205,431,000 after purchasing an additional 178,939 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Down 0.4 %

MRNA stock opened at $30.96 on Friday. Moderna, Inc. has a twelve month low of $29.25 and a twelve month high of $170.47. The business’s fifty day moving average is $37.30 and its 200-day moving average is $51.12. The company has a market cap of $11.94 billion, a P/E ratio of -3.34 and a beta of 1.59.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Bank of America lowered their price target on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research note on Tuesday, February 11th. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research note on Monday, November 18th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Berenberg Bank upped their price objective on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Finally, UBS Group lowered their price objective on Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $60.63.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.